Search
Displaying 771–780 of 851 results for “vision connection”
-
The Usher 1B Workshop is designed to bring together leading experts from academia and industry, to discuss openly, and in detail, what is known about Usher 1B disease pathology, disease models, clinical characteristics and therapeutic approaches.
-
Nanoscope Therapeutics Launches Phase 2b Clinical Trial for Optogenetic Therapy
Research NewsWhile the trial is for people with RP, the company hopes it will also benefit people with other retinal degenerative diseases
-
Foundation News
This June 30th exclusive conversation and acoustic performance by Grammy-nominated rocker Grace Potter will raise awareness and funds to find treatments and cures for blinding diseases.
-
Biogen’s Phase 3 Clinical Trial for its Choroideremia Gene Therapy Doesn’t Meet Endpoints
Research NewsAdditional results from the trial will be reported at a future scientific meeting
-
Foundation News
The free webinar for eye care professionals, on June 21, will feature some of the intriguing and innovative research efforts underway for inherited retinal diseases and AMD.
An overview of the Foundation’s no-cost genetic testing program will also be presented.
-
ARVO 2021 Highlight: CRISPR/Cas9 Therapy Emerging for Dominant RP Caused by RP1 Mutations
Research NewsGene-editing approaches are often better suited for autosomal dominant retinal diseases than gene replacement therapies
-
Ambitious Swimmer Spreading Optimism
Beacon Stories26-year-old Becca is a two-time Paralympic swimmer for Team USA, diagnosed with Usher syndrome type 1 (USH1) at only four years old. But she has never let her diagnosis with Usher syndrome stop her from doing exactly what she puts her mind to.
-
Investing in Cures Summit 2021
The 2021 Investing in Cures Summit (ICS) convenes key stakeholders of the Foundation Fighting Blindness and RD Fund to learn from the world’s leading industry, clinical and retinal science innovators poised to take emerging therapies across the finish line.
-
Genentech’s Faricimab Performs Well in Phase 3 Clinical Trials for Wet AMD
Research NewsCompany will seek marketing approval for the emerging therapy
-
ProQR Completes Enrollment in Phase 2/3 Clinical Trial of RNA Therapy for LCA10
Research NewsCompany also announced progress in enrollment for Phase 1 / 2 clinical trials for emerging USH2A and RHO RNA therapies.
